DGX / Reasons to Retain Quest Diagnostics (DGX) Stock for Now

Quest Diagnostics' (DGX) base business growth reflects the company's ongoing efforts to partner with health plans, hospitals and physicians amid a con more_horizontal

Quest Diagnostics (DGX) came out with quarterly earnings of $2.22 per share, beating the Zacks Consensus Estimate of $2.19 per share. This compares to more_horizontal

Quest Diagnostics Inc. DGX, -1.84% said Tuesday its third-quarter profit dropped by 12.2% to $225 million, or $1.96 a share, from $256 million, or $2. more_horizontal

Quest Diagnostics (DGX) third-quarter 2023 results are likely to reflect continued strength in the base business. more_horizontal

Quest Diagnostics' (DGX) recent acquisition of New York-Presbyterian's outreach assets adds to volume growth within Physician Lab Services. more_horizontal

Quest Diagnostics (DGX) latest deal will boost dialysis laboratory testing and reduce the laboratory costs of dialysis programs for ESRD patients. more_horizontal

SECAUCUS, N.J. , Oct. 4, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information servi more_horizontal

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Neverthe more_horizontal